Roundup of Antibody Biotech Deals in March 2026

March 2026 saw antibody dealmaking for immune cell engagers and autoimmune applications. T-cell engager formats, particularly bispecific and trispecific antibodies, featured across both licensing and M&A activity. The month also highlighted growing research between antibodies and targeted protein degradation, alongside early-stage investment in next-generation platforms spanning computational design, delivery, and novel biologic production systems.

🔍 March Deal Signals

• T-cell engagers (CD3-based) emerge as a dominant modality, especially in autoimmune disease

• Increasing M&A activity focused on platform acquisition and clinical-stage assets

• Continued expansion of antibody applications beyond oncology into immunology and rare diseases

• Growing integration of antibody therapeutics with protein degradation technologies

• Strong early-stage funding activity supporting next-generation discovery and engineering platforms

🤝 M&A & Strategic Acquisitions

• Novartis → Excellergy – Acquisition to advance a next-generation anti-IgE trifunctional antibody program (ECRI), with total deal value up to $2B. 

• Gilead Sciences → Ouro Medicines – Acquisition adding OM336 (gamgertamig), a BCMAxCD3 T-cell engager for autoimmune diseases, valued up to $2.18B. 

• Gyre Therapeutics → Cullgen – Acquisition to gain a targeted degrader-antibody conjugate platform and pipeline, valued at $300M. 

💵 Licensing & Option Deals

• Antengene × UCB – Global licensing agreement for ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases, with potential value up to $1.1B.

• Kali Therapeutics × Sanofi – Worldwide license for a trispecific T-cell engager targeting autoimmune diseases, valued at up to $1.2B. 

💸 Financings, Launches & Company Formation

• Prolium Bioscience – Launched with $50M and initiated clinical dosing of PRO-203, a CD20xCD3 T-cell engager for autoimmune disease.

• Antiverse – Raised $9.3M Series A to develop antibodies for undruggable targets, alongside a research collaboration with the Cystic Fibrosis Foundation.

• Poplar Therapeutics – Closed $45M Series A extension to advance PHB-050, a next-generation anti-IgE therapy.

• Laigo Bio – Completed €17M seed financing to develop SureTAC-based targeted protein degradation therapies, including bispecific antibodies.

• CytoDyn – Raised $17.5M to support continued development of leronlimab, a CCR5-targeting monoclonal antibody.

• Excalipoint Therapeutics – Launched with $68.7M seed funding to advance T-cell engager programs, including a trispecific antibody for oncology.

• Crossbow Therapeutics – Raised $77M Series B to develop TCR-mimetic antibody therapies for cancer.

• Mestag Therapeutics – Secured $40M financing to advance MST-0312, a FAP-targeted bispecific antibody.

• iDEL Therapeutics – Launched with €9M seed financing to advance oncology programs based on direct cytosolic transfer technology.

• Immutrin – Raised £65M Series A to develop next-generation antibody therapies for ATTR amyloidosis.

• Neion Bio – Emerged from stealth with a platform for producing recombinant biologics in eggs.

• Scala Biodesign – Raised $16M Series A to advance computational protein design technologies for antibody therapeutics.